Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle

On Wednesday, Prime Medicine emerged victorious in a legal dispute against Beam Therapeutics. Following the court decision, Prime's shares surged, while Beam's stock plummeted. The clash between the two gene editing companies has captured attention, especially since Beam is considered a powerhouse in the industry. The legal battle's outcome has clearly impacted the market, reflected in the contrasting stock movements of Prime and Beam.